通过人类乳头瘤病毒疫苗接种和宫颈筛查计划预防宫颈癌

Mark McGowan, Peter Otott
{"title":"通过人类乳头瘤病毒疫苗接种和宫颈筛查计划预防宫颈癌","authors":"Mark McGowan,&nbsp;Peter Otott","doi":"10.1016/j.ogrm.2023.11.001","DOIUrl":null,"url":null,"abstract":"<div><p><span>Cervical cancer causes more than 300,000 deaths worldwide every year, affecting women from a young age. It has a well-understood natural history, caused by HPV, which is estimated to be responsible for 99.8% of cases. In order to decrease the number of UK cervical cancer cases, a national screening programme was launched in 1988. Women between the ages of 25 and 64 are invited for </span>cervical screening<span>. A primary high-risk HPV testing approach is used, whereby samples are only tested for cytology<span><span> if they are positive for high-risk HPV. The national HPV vaccination programme was introduced in 2008 in the UK. The Gardasil 9 vaccine is offered at year 8 in UK schools (ages 12–13 years old) to boys and girls. These programmes have been a huge success in reducing the number of cervical cancer cases. However, still only 70% of eligible women attend their screening appointments. To further increase the proportion of women reached by the programme, further alternatives are currently tested, including home vaginal swab tests and </span>urinary HPV testing.</span></span></p></div>","PeriodicalId":53410,"journal":{"name":"Obstetrics, Gynaecology and Reproductive Medicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Preventing cervical cancer through human papillomavirus vaccination and cervical screening programmes\",\"authors\":\"Mark McGowan,&nbsp;Peter Otott\",\"doi\":\"10.1016/j.ogrm.2023.11.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span>Cervical cancer causes more than 300,000 deaths worldwide every year, affecting women from a young age. It has a well-understood natural history, caused by HPV, which is estimated to be responsible for 99.8% of cases. In order to decrease the number of UK cervical cancer cases, a national screening programme was launched in 1988. Women between the ages of 25 and 64 are invited for </span>cervical screening<span>. A primary high-risk HPV testing approach is used, whereby samples are only tested for cytology<span><span> if they are positive for high-risk HPV. The national HPV vaccination programme was introduced in 2008 in the UK. The Gardasil 9 vaccine is offered at year 8 in UK schools (ages 12–13 years old) to boys and girls. These programmes have been a huge success in reducing the number of cervical cancer cases. However, still only 70% of eligible women attend their screening appointments. To further increase the proportion of women reached by the programme, further alternatives are currently tested, including home vaginal swab tests and </span>urinary HPV testing.</span></span></p></div>\",\"PeriodicalId\":53410,\"journal\":{\"name\":\"Obstetrics, Gynaecology and Reproductive Medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Obstetrics, Gynaecology and Reproductive Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1751721423001872\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obstetrics, Gynaecology and Reproductive Medicine","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1751721423001872","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

宫颈癌每年在全球造成 30 多万人死亡,影响着年轻女性。宫颈癌的自然病史非常清楚,是由人乳头瘤病毒引起的,据估计,99.8% 的病例都是由人乳头瘤病毒引起的。为了减少英国宫颈癌病例的数量,1988 年启动了一项全国筛查计划。年龄在 25 岁至 64 岁之间的妇女被邀请进行宫颈筛查。采用的是高危 HPV 初筛检测方法,即样本只有在高危 HPV 检测呈阳性时才进行细胞学检测。英国于 2008 年推出了全国性的 HPV 疫苗接种计划。英国学校在八年级(12-13 岁)为男生和女生提供加德西 9 号疫苗。这些计划在减少宫颈癌病例方面取得了巨大成功。但是,仍然只有 70% 的符合条件的妇女参加了筛查预约。为了进一步提高该计划惠及的妇女比例,目前正在测试更多的替代方法,包括家庭阴道拭子测试和尿液人乳头瘤病毒检测。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Preventing cervical cancer through human papillomavirus vaccination and cervical screening programmes

Cervical cancer causes more than 300,000 deaths worldwide every year, affecting women from a young age. It has a well-understood natural history, caused by HPV, which is estimated to be responsible for 99.8% of cases. In order to decrease the number of UK cervical cancer cases, a national screening programme was launched in 1988. Women between the ages of 25 and 64 are invited for cervical screening. A primary high-risk HPV testing approach is used, whereby samples are only tested for cytology if they are positive for high-risk HPV. The national HPV vaccination programme was introduced in 2008 in the UK. The Gardasil 9 vaccine is offered at year 8 in UK schools (ages 12–13 years old) to boys and girls. These programmes have been a huge success in reducing the number of cervical cancer cases. However, still only 70% of eligible women attend their screening appointments. To further increase the proportion of women reached by the programme, further alternatives are currently tested, including home vaginal swab tests and urinary HPV testing.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Obstetrics, Gynaecology and Reproductive Medicine
Obstetrics, Gynaecology and Reproductive Medicine Medicine-Obstetrics and Gynecology
CiteScore
0.90
自引率
0.00%
发文量
67
期刊介绍: Obstetrics, Gynaecology and Reproductive Medicine is an authoritative and comprehensive resource that provides all obstetricians, gynaecologists and specialists in reproductive medicine with up-to-date reviews on all aspects of obstetrics and gynaecology. Over a 3-year cycle of 36 issues, the emphasis of the journal is on the clear and concise presentation of information of direct clinical relevance to specialists in the field and candidates studying for MRCOG Part II. Each issue contains review articles on obstetric and gynaecological topics. The journal is invaluable for obstetricians, gynaecologists and reproductive medicine specialists, in their role as trainers of MRCOG candidates and in keeping up to date across the broad span of the subject area.
期刊最新文献
Editorial Board Editorial Board Genomics and hereditary cancer syndromes in women's health: a focus on gynaecological management Self-assessment questions Management of antepartum haemorrhage
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1